CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry

Description

Prospective observational registry for an adolescent cohort with AD under the care of a dermatology provider. Approximately 1500 subjects and 75 clinical sites in North America and select European countries will be recruited to participate with no defined upper limit for either target.

Conditions

Atopic Dermatitis

Talk to us

Study Overview

On this page

Study Details

Study overview

Prospective observational registry for an adolescent cohort with AD under the care of a dermatology provider. Approximately 1500 subjects and 75 clinical sites in North America and select European countries will be recruited to participate with no defined upper limit for either target.

CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry

CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry

Condition
Atopic Dermatitis
Intervention / Treatment

-

Contacts and Locations

Waltham

CorEvitas, LLC, Waltham, Massachusetts, United States, 02451

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * To be eligible to participate in this registry, an individual must meet all the following criteria:
  • 1. Has been diagnosed with moderate to severe atopic dermatitis by a dermatologist or a qualified dermatology practitioner.
  • 2. Is 12 - 15 years of age at the time of enrollment.
  • 3. Meets one of the following conditions at the time of enrollment:
  • 1. Has started taking a new Enrollment Eligible Medication within 6 months prior to the Enrollment visit. A new medication is a medication that the subject has never taken before.
  • 2. Is prescribed a new Enrollment Eligible Medication at the Enrollment visit. A new medication is a medication that the subject has never taken before.
  • 1. Is participating or planning to participate in a blinded clinical trial for an AD drug.

Ages Eligible for Study

12 Years to 15 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

CorEvitas,

Study Record Dates

2099-12-31